{"groups":[{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"FG000","title":"Treatment Cohort 1 AA & GBM"},{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"FG001","title":"Treatment Cohort 2 Anaplastic PXAs"},{"description":"Pre-op -14 days: Encorafenib 450mg QD and Binimetinib 45mg BID last dose of both drugs 2hrs prior to surgery\n\nTumor; research blood; CSF samples\n\npost surgery: Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"FG002","title":"Surgical Arm"},{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"FG003","title":"Treatment Cohort 3 Other Tumors"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"pt had to stop treatment on this study but continued treatment off this study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"1 patient on Treatment Cohort 2 anaplastic PXAs was still on treatment at the time of the mandated stop of treating patients by NCI/CTEP. This patient continues to receive treatment but not on this study.","recruitmentDetails":"Patients were accrued January 2020 -April 30 2022. The trial terminated early due to mandated closed to accrual for all ABTC studies as of 4/30/21. ABTC is closed to accrual and treatment on October 31 2023. The final trial clinical data includes a total of 5 subjects enrolled into the trial. Per original trial design, 56 subjects were required for the primary objective of the trial. The termination of the trial is considered an administrative termination."}